Insider Selling: Krystal Biotech (NASDAQ:KRYS) Director Sells $4,953,719.50 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) Director Dino Rossi sold 18,950 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $261.41, for a total value of $4,953,719.50. Following the transaction, the director owned 78,691 shares of the company’s stock, valued at $20,570,614.31. This trade represents a 19.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $272.50 on Thursday. The firm has a market capitalization of $7.97 billion, a PE ratio of 39.78 and a beta of 0.49. The firm’s 50-day moving average is $267.44 and its two-hundred day moving average is $212.98. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. The business had revenue of $107.11 million during the quarter, compared to analyst estimates of $105.30 million. Analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Hantz Financial Services Inc. lifted its stake in Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after buying an additional 179 shares during the last quarter. Bessemer Group Inc. increased its holdings in shares of Krystal Biotech by 106.9% in the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after acquiring an additional 77 shares during the period. AdvisorNet Financial Inc purchased a new stake in Krystal Biotech in the 3rd quarter valued at $30,000. Salomon & Ludwin LLC purchased a new stake in Krystal Biotech in the 3rd quarter valued at $33,000. Finally, First Horizon Advisors Inc. boosted its stake in Krystal Biotech by 212.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock worth $34,000 after purchasing an additional 166 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on KRYS shares. HC Wainwright reiterated a “buy” rating and issued a $310.00 price objective (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. The Goldman Sachs Group increased their price target on Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Citigroup lifted their price objective on Krystal Biotech from $336.00 to $371.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Guggenheim upped their target price on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Krystal Biotech in a report on Friday, January 9th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Krystal Biotech has a consensus rating of “Moderate Buy” and a consensus target price of $326.25.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.